Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

Completed · Not applicable

Conditions studied: Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema

In brief

To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF). Secondarily, the study monitors the results of subjective and objective findings as it applies to the non-blinded deployment of autologous SVF for various inflammatory and/or degenerative conditions including select orthopedic, neurologic, urologic and cardio-pulmonary conditions. SVF deployments include intra-venous, intra-articular, and soft tissue injections.

Key facts

Study ID

NCT01953523

Run by

Elliot Lander

People needed

3000

Starts

2013-09-02

Expected to finish

2017-01-01

Last updated by the study team

2018-09-25

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patient must be age 16 or older
• Patient must have a degenerative disease or inflammatory disease that meets criteria for treatment under the IRB which includes: Arthritis, Auto-immune disease,COPD, Cardiomyopathy, Peyronies Disease,Interstitial Cystitis, Erectile Dysfunction, and Neurodegenerative disease such as Parkinsons, ALS, Neuropathy.
• Patient must be healthy enough to tolerate a local anesthetic

You may not qualify if…

• Patient must not have active cancer
• Patient must not have active infection

Where it is running

• California Stem Cell Treatment Center — Rancho Mirage, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.